前收市價 | 2.0000 |
開市 | 2.0000 |
買盤 | 0.5500 |
賣出價 | 3.0000 |
拍板 | 5.00 |
到期日 | 2024-06-21 |
今日波幅 | 2.0000 - 2.0000 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Penny stocks carry a great deal of risk. It’s why investors are often told to steer clear of them. Many penny stocks typically trade over the counter and rarely on a major exchange. And about 90% of them fail. It’s why we include a warning at the tail-end of the article, and why the U.S. SEC has issued warnings against them. While you may get lucky and uncover the next Apple (NASDAQ:AAPL) or Advanced Micro Devices (NASDAQ:AMD) in the bunch, you have to dig through a lot of garbage. That’s not to
Allogene (ALLO) reports drab first-quarter 2024 results. The company secures the development and marketing rights to its CD19 oncology program in Europe.